Seniors appear to be filling incremental prescriptions, given additional drug coverage.
We anticipate a relief rally for pharmaceutical stocks.
It is possible that pharmaceutical group stock momentum could carry (Lilly) higher, but we believe the risk/reward warrants a neutral rating.
Instead, it was driven by the core business and a lower tax rate.
